Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 4 - You Need To See This

Hims & Hers Stock: Buy the Dip or Wait It Out?

Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform.

MarketBeat

Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

MarketBeat

5 Momentum Stocks to Buy Now

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of 2025.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Stock Chart Points to Strong Bullish Continuation

Hims & Hers Health, Inc. stock price action shows strongly bullish signs in May and could be ready to hit new highs before the 2nd half starts.

MarketBeat

Hims & Hers Stock Rises on Fundamentals and Squeeze Potential

Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum.

MarketBeat

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

MarketBeat

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

MarketBeat Week in Review – 03/03 - 03/07

Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue

MarketBeat

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

MarketBeat

Hims & Hers Health Sparks Investors Interest with Unusual Options Trading

Hims and Hers Health produced sterling results on Feb. 24, spurring huge interest in HIMS call options trading. Barchart reported an unusual volume today in HIMS call options that expire on March 14.

Barchart

Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.

MarketBeat

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

MarketBeat Week in Review – 02/17 - 02/21

Stocks were volatile this week as bad news gave investors a reason to sell; that volatility will continue next week with key retail earnings and inflation news

MarketBeat

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

MarketBeat

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Hims & Hers Health: A Stock to Trade or Own?

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

MarketBeat

Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025

StockNews.com

3 Telemedicine Stocks Making Healthcare More Accessible

The telemedicine industry is transforming healthcare with digital platforms, growing consumer demand, and innovative care delivery models. As the sector evolves, telemedicine stocks like Doximity (DOCS), Hims & Hers Health (HIMS), and GoodRx Holdings (GDRX) are well-positioned to capitalize on this trend. Read on….

MarketBeat

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

Benzinga

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

MarketBeat

2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

StockNews.com

3 Digital Health Companies Enhancing Patient Engagement

The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are strategically positioned to thrive in the sector, making them attractive investment opportunities. Read on….

1 … 3 4 5 6

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.